Cargando…
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
Due to their favourable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer. However, the oestrogen agonist effects of the available selective oestrogen receptor modulators, such as tamoxifen, and the development...
Autores principales: | Osborne, C K, Wakeling, A, Nicholson, R I |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750773/ https://www.ncbi.nlm.nih.gov/pubmed/15094757 http://dx.doi.org/10.1038/sj.bjc.6601629 |
Ejemplares similares
-
A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
por: Addo, S, et al.
Publicado: (2002) -
ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data
por: Robertson, J F R
Publicado: (2001) -
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018) -
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011) -
Oestrogen receptors in primary breast cancer.
por: Williams, M. R., et al.
Publicado: (1985)